These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8188035)

  • 1. [Immunosuppressive action of polyamines in patients with chronic myeloid leukemia].
    Shardakov VI; Dem'ianova VT; Kopaneva TG
    Gematol Transfuziol; 1994; 39(1):9-11. PubMed ID: 8188035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.
    Rojas JM; Wang L; Owen S; Knight K; Watmough SJ; Clark RE
    Exp Hematol; 2010 Dec; 38(12):1209-18. PubMed ID: 20854875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Suppressive effect of circulating immune complexes on cytotoxicity of blood lymphocytes in patients with chronic myeloid leukemia].
    Guseva SA; Fed'ko AA; Volobueva ZV
    Gematol Transfuziol; 1992 Feb; 37(2):10-2. PubMed ID: 1426900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myeloid leukemia as an immunological target.
    Lim SH; Coleman S
    Am J Hematol; 1997 Jan; 54(1):61-7. PubMed ID: 8980262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in the content of bound polyamines in the whole blood in patients with chronic leukemia].
    Voronchikhina LD; Dem'ianova VT; Berdinskikh NK; Kolupaeva NV
    Vrach Delo; 1988 Sep; (9):64-6. PubMed ID: 3213003
    [No Abstract]   [Full Text] [Related]  

  • 8. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
    Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
    Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.
    Li Q; Wu Y; Fang S; Wang L; Qi H; Zhang Y; Zhang J; Li W
    Cancer Gene Ther; 2015 May; 22(5):227-37. PubMed ID: 25837664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
    Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
    J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
    Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
    Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia.
    Basbous S; Levescot A; Piccirilli N; Brizard F; Guilhot F; Roy L; Bourmeyster N; Gombert JM; Herbelin A
    J Pathol; 2016 Nov; 240(3):262-268. PubMed ID: 27513300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
    Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
    Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.
    Oka T; Sastry KJ; Nehete P; Schapiro SJ; Guo JQ; Talpaz M; Arlinghaus RB
    Leukemia; 1998 Feb; 12(2):155-63. PubMed ID: 9519777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
    Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
    Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE
    Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the CDR3 structure of the Vβ21 T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia.
    Zha X; Chen S; Yang L; Li B; Chen Y; Yan X; Li Y
    Hum Immunol; 2011 Oct; 72(10):798-804. PubMed ID: 21820025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.